MSD Korea acquired an approval for its anti PD-1 antibody from the Ministry of Food and Drug Safety

Published: 2015-03-26 14:04:36

Updated: 2015-03-26 14:04:36

“We will represent changes of the paradigm with our 3^rd generation anticancer drug overcoming side effects of systemic cancer chemotherapy and tolerance risks of targeted argents.”

MSD Korea (CEO Dong-wook Hyun) acquired the first approval for its anti PD-1 antibody, Keytruda TM (pmbrolizumab), from the Ministry of Food and Drug Safety; the treatment is targeting patients who are not possible ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.